Literature DB >> 3415428

Having a dream. A research strategy for DSM-IV.

R L Spitzer1, J B Williams.   

Abstract

Psychiatric research has had a major impact on both DSM-III and its revision (DSM-III-R). We propose a strategy to maximize the impact of psychiatric research on DSM-IV. This strategy is an elaboration of a study design that was particularly helpful in developing criteria for several of the problematic diagnostic categories of DSM-II-R. The strategy, called a "multiplex study design," employs (1) multiple collaborating centers, (2) multiple experts in the diagnoses being studied at each site, and (3) multiple diagnostic criteria sets so that alternative definitions of disorders can be compared in terms of (4) multiple external validity criteria, such as familial aggregation, course, and differential response to treatment. This strategy is a particularly efficient method for providing an empiric base for further revisions in our official classification of mental disorders.

Entities:  

Mesh:

Year:  1988        PMID: 3415428     DOI: 10.1001/archpsyc.1988.01800330105013

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  4 in total

1.  Brief report: Interrater reliability of clinical diagnosis and DSM-IV criteria for autistic disorder: results of the DSM-IV autism field trial.

Authors:  A Klin; J Lang; D V Cicchetti; F R Volkmar
Journal:  J Autism Dev Disord       Date:  2000-04

Review 2.  Somatization disorder: defining its role in clinical medicine.

Authors:  R C Smith
Journal:  J Gen Intern Med       Date:  1991 Mar-Apr       Impact factor: 5.128

3.  ADHD symptom subtypes in children with pervasive developmental disorder.

Authors:  Kenneth D Gadow; Carla J DeVincent; John Pomeroy
Journal:  J Autism Dev Disord       Date:  2006-02

4.  Preserving the clinician-researcher interface in the age of RDoC: the continuing need for DSM-5/ICD-11 characterization of study populations.

Authors:  Michael B First
Journal:  World Psychiatry       Date:  2014-02       Impact factor: 49.548

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.